References
- Almeida L, Soares-da-Silva P. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. Drugs R D 2003;4:207-17
- Almeida L, Soares-da-Silva P. Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects. J Clin Pharmacol 2003;43:1350-60
- Silveira P, Vaz-da-Silva M, Almeida L, et al. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. Eur J Clin Pharmacol 2003;59:603-9
- Almeida L, Vaz-da-Silva M, Silveira P, et al. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. Clin Neuropharmacol 2004;27:17-24
- Vaz-da-Silva M, Loureiro AI, Nunes T, et al. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-O-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg: randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Drugs R D 2008;9:435-46
- Nunes T, Machado R, Rocha JF, et al. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel COMT inhibitor, and controlled release levodopa/benserazide: a single-centre, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. Clin Ther 2009;31:2258-71
- Almeida L, Falcao A, Vaz-da-Silva M, et al. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Eur J Clin Pharmacol 2008;64:961-6
- Ferreira J, Almeida L, Cunha L, et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase (COMT) activity and motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 2008;31:2-18
- Loureiro AI, Bonifacio MJ, Fernandes-Lopes C, et al. Human metabolism of nebicapone (BIA 3-202), a novel catechol-O-methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metab Dispos 2006;34:1856-62
- Palma PN, Bonifacio MJ, Almeida L, et al. Restoring dopamine levels. In: Smith HJ, Simons C, Sewell RDE, eds. Protein Misfolding in Neurodegenerative Diseases. Boca Raton, FL, USA: CRC Press, 2008:415-45
- Bruguerolle B. Chronopharmacokinetics current status. Clin Pharmacokinet 1998;35:83-94
- Ferreira JJ, Almeida L, Cunha L, et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol 2008;31:2-18
- Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-8
- Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-71
- Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997;49:665-71
- Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 2000;57:263-7